INTRODUCTION
The National Health Service (NHS) faces severe funding constraints now and in the medium term. The forecast reduction in resources provides an enormous challenge to NHS organisations and staff. Service redesign can save money and improve quality but much depends on how care is co-ordinated and the way services are implemented in a local setting. 1 2 NHS decisionmakers need to consider not only the effectiveness and costeffectiveness of any initiative but also efficient implementation. Enhanced recovery programmes (also known as ERAS, fast track, multimodal, rapid or accelerated recovery programmes) seek to deliver an optimal Strengths and limitations of this study ▪ Enhanced recovery programmes have been adopted with enthusiasm by the NHS as a means to achieving productivity gains and cost savings. This evolution makes combining studies over different periods and interpreting results of earlier studies in relation to the current context more difficult. ▪ The evidence base to support such widespread implementation suggests possible benefits in terms of reduced length of hospital stay, fewer postoperative complications, reduced readmissions and improved patient outcomes. ▪ Although there is a reasonable volume of evidence evaluating enhanced recovery programmes in colorectal surgery, robust evidence is sparse. Optimal care is certainly the right thing to do, but the evidence does not identify which enhanced recovery programme elements and combinations of elements are most effective. ▪ Findings relating to other outcomes, costs of enhanced recovery programmes, experience in using the programmes, and patient experience were limited by generally poor quality evidence and poor reporting. As such, conclusions on which combinations provide greatest gains and how best to implement them cannot be made.
pathway (covering the preoperative, intraoperative and postoperative periods) that is focused on optimal recovery and discharge for patients. The approach was pioneered in Denmark in the late 1990s for patients undergoing colorectal surgery 3 and is now spreading to other surgical pathways such as orthopaedic, urology and gynaecology.
Enhanced recovery programmes have been delivered in the UK NHS since the early 2000s. Implementation has to date been variable despite the support of the Department of Health and more recently the Royal Colleges. In 2011, 14 innovation sites were established as part of the Enhanced Recovery Partnership Programme. These sites acted as pathfinders for implementation; some sites were self-selecting and others were encouraged to join. The aim was to raise the profile, promote the benefits and inform the uptake of enhanced recovery for elective surgical care across the NHS. These sites had little or no experience in enhanced recovery pathways. It is likely that this variation seen across these sites reflects the complexity of enhanced recovery programmes themselves and issues around implementing change in established surgical pathways . Differences in programme implementation may also reflect differences between surgical specialities. Set against the benefits of enhanced recovery programmes are concerns that discharging patients too soon after surgery could increase complications and readmissions, thereby worsening patient experience and potentially health outcomes, and increasing pressure on primary and/or secondary healthcare services.
Before embarking on adoption of an enhanced recovery programme, NHS managers and clinicians need to be fully aware of the strength of the underlying evidence. They need to have a clear understanding of how best to implement such programmes and the likely implications for service delivery within finite budgets and considering the need for equity of access. The aim of this project was to conduct a rapid synthesis of the evidence on the clinical and cost-effectiveness of enhanced recovery programmes, and the implementation, delivery and impact of such programmes in secondary care settings in the UK.
METHODS
Eight databases, including DARE, NHS EED and MEDLINE were searched to from 1990 to March 2013 without language restrictions. The PROSPERO database was searched to identify ongoing systematic reviews. Relevant reports and guidelines were screened for further studies. Reference lists of retrieved articles, reviews and evaluations were scanned, and relevant individuals contacted for additional evidence. Systematic reviews, RCTs not included in the systematic reviews, economic evaluations and UK NHS cost analysis studies were included if they evaluated the impact of enhanced recovery programmes (encompassing different combinations of the main preoperative, intraoperative and postoperative pathway elements described by the Enhanced Recovery Partnership Programme) 4 on health-related or cost-related outcomes. Eligible studies included patients undergoing elective surgery in an acute hospital in the UK NHS or a comparable healthcare system. Comparators were only relevant to clinical and cost-effectiveness evaluations, and included conventional (usual/standard) care without a structured multimodal enhanced recovery patient pathway (as defined in the included studies). Case studies, impact assessments and surveys of patient experience that documented the experience of implementing enhanced recovery in a UK setting were also eligible.
Quality assessment of systematic reviews, RCTs and economic evaluations was based on existing CRD critical appraisal methods (http://www.crd.york.ac.uk/crdweb/ HomePage.asp; CRD, 2009). Cost analysis studies, studies of patient experience and case studies of implementation were not formally quality assessed.
All stages of the review process were performed by one researcher and checked by a second. Disagreements between reviewers were resolved by discussion or by recourse to a third reviewer where necessary.
The type and range of evidence precluded metaanalysis and we therefore performed a narrative synthesis, differentiating clinical outcomes (eg, mobilisation, mortality and morbidity and length of hospital stay), patientreported outcomes (eg, patient experience and satisfaction), resource use in secondary care (eg, workforce utilisation and costs) and implementation case studies.
RESULTS

Seventeen systematic reviews
5-21 and 12 additional RCTs [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were included in the evidence on clinical effectiveness (see figure 1 : flow diagram). The quality of the systematic reviews varied and the additional RCTs were considered to be at high risk of bias (see tables 1 and 2). One RCT was a four arm trial; this was the only multicentre trial, the remaining trials were small, single centre trials. 35 We included 15 case studies of implementation of ERAS in NHS settings, and evaluations of the 14 Enhanced Recovery Partnership Programme innovation sites. In addition, 10 relevant economic evaluations were also included (summary evidence tables are available on request from the review authors). Most of the evidence focused on colorectal surgery.
Where reviews reported the number of included patients, sample sizes ranged between 99 and 5747 patients in the ERAS group and between 99 and 1062 in comparator groups. Most individual RCTs analysed fewer than 100 patients (range 44-597 patients). Where indications for surgery were reported in systematic reviews and individual RCTs, most trials were in patients with cancer. Where reported, patients were adults within similar age ranges. Follow-up was generally up to 30 days post discharge.
The number and combination of ERAS elements varied considerably across all types of evidence; ranging from 4 to 14 elements across systematic reviews and from 10 to 14 elements across individual RCTs (see full report for details; in press). This highlights the lack of standardisation across ERAS programmes and agreement on what constitutes an ERAS pathway, and will have implications on the overall findings. Only one review assessed compliance with ERAS elements. 7 Ahmed et al 7 noted that, in general, compliance fell during the postoperative period in most of the studies (from around 100% to around 20%). Use of epidural analgesia had the highest levels of compliance across all studies (67-100%). Use of transverse incisions had the lowest levels of compliance (around 25%). Reasons for differences in compliance and waning of compliance were not measured in the reviews. None of the reviews assessed patient compliance, including adherence to preoperative advice to ensure fitness for surgery.
Despite the large number of studies, robust evidence was sparse (see online supplementary tables S1 and S2; full outcome details are available in the full review; in press). Seven reviews in colorectal surgery performed meta-analyses and showed a significant mean reduction in primary or total length of stay that ranged from 1.56 days (95% CI 0.50 to 2.61 days) 19 to 3.75 days (95% CI 5.11 to 2.40 days). 18 Evidence from individual RCTs in colorectal surgery also suggest reduced length of hostpital stay following an ERAS programme (mean length of stay 4.15 to 6.43 days) compared to conventional care (mean length of stay 6.6 to 11.7 days). There were no significant differences in reported readmission rates, but it was unclear how readmissions were defined and measured in the reviews and RCTs.
Other surgical specialties showed greater variation in reported reductions in length of stay, but this is likely to reflect the greater uncertainty due to the more limited evidence base for these specialties. Statistical heterogeneity varied between reviews and was often not formally explored, but may have reflected differences in ERAS protocols, lack of compliance with important ERAS elements, and differences in surgical populations and procedures.
Deaths were rare and no significant differences between treatment groups were found in the systematic reviews and additional RCTs, regardless of surgical specialty. Morbidity was defined differently across systematic reviews and RCTs; rates between treatment groups were sometimes inconsistent, but generally indicated no statistically significant differences.
Mobilisation rates were inconsistent across systematic reviews, but most reported no significant differences in time to mobilisation between treatment groups. Mobilisation was rarely reported as an outcome in the additional RCTs.
Where systematic reviews and additional RCTs assessed quality of life and patient experience/satisfaction, equivocal findings were reported. Evidence on reintervention rates, pain and resource use was lacking in systematic reviews and RCTs.
Other reviews A systematic review in colorectal surgery, identified after the last literature search, showed similar findings to the systematic reviews discussed above. 36 Mean length of primary hospital stay was statistically significantly reduced in ERAS patients; mean difference (MD) −2.44 (95% CI −3.06 to −1.83; 11 RCTs) but with significant statistical heterogeneity (I 2 =88%). There was no evidence to suggest increased rates of readmissions, complications and mortality. Some of the individual RCT results for primary length of stay did not appear to be consistent with results reported in other systematic reviews, and this may have impacted on the estimated reduction in length of primary hospital stay. 36 Two reviews 37 38 focusing on individual ERAS elements were identified, of which highlighted the lack of evidence on the full ERAS pathway and the lack of compliance with ERAS protocols. Details can be found in the full review (in press). 
Case studies Ten of 14 UK NHS innovation sites provided adequate data for inclusion in this section. [39] [40] [41] Fifteen case studies of implementation of ERAS in NHS settings, and 11 NHS trusts (mostly in colorectal surgery) provided evidence relating to the implementation of an ERAS programme within their Trust. Full results and evidence tables are presented in the full review (in press).
There were variations in practice in terms of numbers and combinations of ERAS elements implemented; the most frequently implemented programme elements in the case studies were preadmission information/counselling and early postoperative mobilisation. Available evidence did not address which enhanced recovery elements and combinations of elements were most effective. Substantial variation in what constitutes an enhanced recovery programme within and between different surgical specialities, and difficulties in implementing certain ERAS components, suggest that the enhanced recovery pathway may be used as a framework and adapted to suit local situations. Evidence on compliance/adherence to enhanced recovery programmes was lacking.
Case studies identified the factors believed to act as barriers or facilitators to implementing an ERAS programme. Barriers to implementation included resistance to change from patients and staff, lack of funding or support from management, 39 42-44 staff turnover, problems arising from poor documentation, the time required to complete documentation and other practical issues.
Facilitators included the presence of a dedicated ERAS project lead/nurse to coordinate and sustain multidisciplinary working and continuity of the pathway, a multidisciplinary team approach and continual education for staff and patients/patient representatives. One innovation site mentioned that it did not offer a 7 day service for enhanced recovery due to staff resources. Patients operated on towards the end of the week may have to wait until after the weekend to be discharged if they need to be seen by any healthcare professionals or social services. The need to sustain multidisciplinary working means that, in the absence of 24/7 working for elective procedures, enhanced recovery programmes will tend to be front loaded into the start of the working week (typically Monday to Thursday). Recent evidence suggests a higher risk of death for patients who have elective surgical procedures carried out later in the working week and at the weekend, 45 the capcity to implement ERAS throughout the working week might ensure continuity of best care and help mitigate against such variation.
We included two published studies of patient experience of ERAS. 46 47 Each study used qualitative research methods to analyse audiotaped material. The two studies provided limited evidence suggesting that patients who were willing to provide feedback took a positive view of their experience of treatment in an ERAS programme. The studies suggested that patients were willing to comment on their experience in a way that can help healthcare providers to identify areas for improvement.
COST-EFFECTIVENESS
Ten economic evaluations in adult populations undergoing various surgical procedures evaluated costs and outcomes over short-time horizons (see online supplementary table S3). [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] All of the evaluations suggested that programmes that achieve a reduction in length of stay are cost saving, and are not to the detriment of patients in terms of complication rates, readmission and health-related quality-of-life. The quality of the clinical studies on which these evaluations were based was variable, but generally poor. The generalisability of the results of these evaluations was limited by a lack of transparency in reporting, and the disparity in standard protocols and what had been evaluated across the settings made it unfeasible to select a cost-effective programme.
DISCUSSION
Statement of principal findings
Overall, the systematic reviews and additional RCTs suggest that length of hospital stay is reduced in ERAS patients compared to patients receiving conventional care. The evidence was based mainly on colorectal surgery and the applicability of findings to other surgical specialities remains less clear. Evidence for colorectal surgery suggests that enhanced recovery programmes may reduce hospital stays by 0.5-3.5 days compared with conventional care.
There were marked differences in length of stay across reviews and individual studies regardless of specialty. These differences may reflect differences in ERAS protocols, compliance to ERAS programmes, healthcare systems and procedures and/or outcome definitions. This raises questions regarding the magnitude of effect of the ERAS protocols on length of stay, which may be overstated in some reviews.
The evidence suggests that ERAS programmes do not compromise patient morbidity, mortality and readmission rates but outcome definitions varied across reviews and individual studies. Such differences make it difficult to determine the reliability and generalisability of the findings.
Equivocal findings were reported for quality of life and patient experience/satisfaction but the evidence was based on few studies, which utilised various methods to measure these outcomes. The limited evidence precludes conclusions on the effects of ERAS protocols on pain, mobilisation and reintervention.
The implementation evidence included resource use in terms of the professionals involved in delivery of enhanced recovery programmes, but details were very limited and did not add to the evidence synthesis. Most case studies were uncontrolled and represent experiences of a sample of centres that chose to report their data; their outcomes may not be representative of those achieved elsewhere in the UK NHS. Their main value as evidence is the light they shed on NHS clinicians' perceptions of requirements for successful implementation and barriers to implementation of ERAS.
The impact of surgical experience and surgical volume on clinical outcomes was not explored and any implications of differences in these areas remain unknown. As enhanced recovery invariably targets the fitter, more mobile patient, frailer patients may not receive parity of access to what may be considered optimal treatment and management. Managers and clinicians considering implementing such programmes should think about the likely implication on equity of access. Whether inequity is an unintended outcome of enhanced recovery, merits further investigation.
Our review of the cost-effectiveness literature suggests that enhanced recovery programmes that achieve a reduction in length of stay may save costs without detrimental effects on complication rates, readmission and health-related quality of life. However, generalisability of the results of the economic evaluations is limited by a lack of transparency in reporting, use of different settings and populations and variable methodology in analyses. Data were lacking for resource use associated with the programmes evaluated and could not usefully inform the review of economic evaluations. In addition, the clinical effectiveness of some of the programmes considered in economic evaluations was not based on robust evidence.
Strengths and weaknesses
The main strength of this study was our use of multiple approaches to acquire and synthesise evidence. The main limitations were poor methodological quality and poor reporting of the included studies, and the inherent difficulty of reviewing a complex intervention in different healthcare systems and surgical specialities. Current methods for synthesising such complex interventions are limited. The methodological limitations and are not discussed here as this was outside the scope of this project, but have been addressed in previous publications. 58 Another complication is that elements of early enhanced recovery programmes have become accepted practice within conventional care. This evolution makes combining studies over different periods and interpreting results of earlier studies in relation to the current context more difficult.
We found a large number of systematic reviews but there was substantial overlap in the included studies and evidence was not as abundant as the existence of multiple systematic reviews suggested. Most of the RCTs were small and not high quality. With the exception of one RCT, the remainder were single centre trials and therefore appear to have been undertaken to support implementation of an enhanced recovery programme in a specific setting rather than being planned as research studies. There were significant clinical and methodological differences between individual trials, and we therefore presented a narrative synthesis. Relatively few trials were conducted in the UK and this may limit the generalisability of evidence to UK NHS settings.
Lack of evidence on important outcomes including pain and quality of life is also an issue for research in this field. Trials tended not to report on adherence to the planned enhanced recovery programme. Assessing adherence to interventions and the impact this has on health outcomes is an important issue which is often overlooked in studies, and is a limitation in the evidence base in this review.
Three additional systematic reviews of effectiveness were brought to our attention during manuscript submission. One systematic review incorporates RCTs in colorectal surgery (Greco, 2013) , 59 one incorporates RCTs and cohort studies in abdominal surgery (Neville, 2014) 60 and one includes RCTs and quasi-RCTs across various surgical specialities (Nicholson, 2014) . 61 The trials included in Greco (2013) 59 and Nicholson (2014) 61 overlap with those included in this review and the findings are consistent. The inclusion of these two reviews would therefore not have significantly altered the findings from this review. Neville (2014) 60 provides some additional data on patient-reported outcomes, including some evidence on post-discharge functional status. However, these outcomes were not frequently reported, and the additional evidence was mainly from study designs that would not have met the inclusion criteria for this review.
An important feature of our review is the inclusion of evidence on the implementation of enhanced recovery programmes in the UK NHS. This evidence has not been synthesised previously and the original programme websites are archived, so future access is not assured. By summarising this evidence, we have ensured that the main findings continue to be publicly available. We sought evidence on the experience of health professionals and patients of a broad range of sources and study types. Important themes emerged from this evidence that may be of value for implementing and sustaining enhanced recovery programmes in UK NHS settings. Owing to the rapid nature of the evidence synthesis, the list of sources searched to identify data on implementation and delivery of enhanced recovery programmes was not exhaustive and we acknowledge that relevant evidence may have been missed. Indeed, evidence from Scotland has been noted and eligible case studies have been identified from the NHS Scotland Quality Improvement Hub website. It should be noted that these are as limited as those included in the review. A qualitative study was brought to our attention at peer review; the study was published after our final search date. Pearsall et al 62 conducted a qualitative study to explore the barriers and enablers in implementing an enhanced recovery after surgery programme in a University hospital in Canada. The themes identified are consistent with those reported in this review.
However, case studies are susceptible to risk of bias. Use of a standard reporting format was a potential strength of the case studies but variation in what each site actually reported ( particularly in terms of evidence of benefit from the introduction of enhanced recovery programmes) reduced the usefulness of the evidence.
We sought to incorporate published and unpublished evidence on patient experiences and views of enhanced recovery programmes. Evaluation of patient experience of care is increasingly important for the NHS, especially in view of unacceptable failures of care such as those highlighted in the Francis Report. 63 Though the evidence was generally positive for enhanced recovery, it was limited by a shortage of studies that used validated measures of patient experience and by study designs that could bias results in favour of enhanced recovery.
A further strength of this study was the consideration of cost-effectiveness evidence, but the nature of the evidence did not permit any analyses. There is a clear need to capture better evaluated data on costs and benefits of enhanced recovery programmes from a clearly stated perspective. A systematic review of economic evaluations 64 was brought to our attention during manuscript publication. The review confirmed the need for welldesigned research to determine the cost-effectiveness of enhanced recovery programmes from the institutional and societal perspectives.
Implications for healthcare
Overall, there is consistent, albeit limited, evidence that enhanced recovery programmes can reduce length of patient hospital stay without increasing readmission rates. Data on reintervention rates and patient-reported outcomes did not suggest significant differences between enhanced recovery and conventional care, but the evidence was very limited and based on small numbers of patients. The lack of evidence on patient outcomes, resource use and costs precludes firm conclusions on the overall value of enhanced recovery programmes.
ERAS does not appear to reduce complication or readmission rates; the only cost benefit may lie in a reduction in post-operative bed days. Optimal care is certainly the right thing to do, but the evidence does not identify which enhanced recovery programme elements and combinations of elements are most effective. As such, conclusions on which combinations provide greatest gains and how best to implement them cannot be made.
The extent to which managers and clinicians considering implementing enhanced recovery programmes can realise reductions and cost savings will therefore depend on length of stays achieved under their existing care pathway. Important themes emerged from the relevant evidence identified on implementation, including the role of ERAS facilitators and the need for full support from management. It appears that these components are essential for the successful implementation and sustained delivery of enhanced recovery programmes in NHS settings. Consideration of potential benefit also needs to take account of the costs of service redesign, the resource use associated with programmes of this nature, the potential for improvement in patient outcomes and the impact on equity of access.
Implications for research
RCTs comparing an enhanced recovery programme with conventional care continue to be conducted and published, although mostly not in the UK. Given the available evidence, further single centre RCTs of this kind are not a priority. Rather, what is needed is improved collection and reporting of how enhanced recovery programmes are implemented, resourced and experienced in NHS settings. Also, exploration into the effect that varying levels of surgical volume and surgical experience and different discharge protocols might have on the success of an enhanced recovery pathway and subsequent outcomes.This will enhance our existing knowledge and understanding and provide evidence to support local decision-making about whether to adopt and how best to implement.
The two groups of implementation case studies included in our synthesis, although all were conducted in the UK, provide very limited information on how enhanced recovery programmes have actually been implemented in UK NHS settings. The standard reporting format originally proposed by The Enhanced Recovery Partnership Programme would enhance the value of future case studies if adhered to. Knowledge of how well the intervention has been implemented (fidelity) is essential for understanding how and why the intervention works and hence how outcomes can be further improved. Assessing fidelity may involve considering not only adherence to the requirements of the programme but also potential moderating factors, such as strategies used to assist delivery of the intervention, quality of delivery and participant responsiveness to new practices. 65 It would be helpful if future innovation programmes used standardised reporting. For multisite programmes, a formal synthesis of findings from all participating sites should be undertaken as part of the evaluative process. This would ensure that the insights and contextual information which can inform the wider spread and adoption (or indeed discontinuation) would be systematically captured in a generalisable format.
Adherence/compliance to elements by staff and patients also requires further investigation. Rigorous data on patients' experiences of enhanced recovery programmes are lacking. Validated tools should be used and administered independently of those providing the service. Efforts should be made to obtain data from representative samples of patients receiving conventional care as well as those treated with enhanced recovery protocols, along with evidence on the experiences of their families/carers.
Evidence relating to the cost-effectiveness of enhanced recovery programmes in UK NHS settings is lacking. While enhanced recovery programmes have the potential to deliver cost savings, improved measurement of costs and benefits is crucial to help decisionmakers decide how best to make optimal use of limited resources.
